Top Markets
#1 GEKKO GEKKO +52.86%
#2 Helium Helium +45.40%
#3 Pons Pons +21.76%
#4 Main Street Yield Main Street Yield +17.48%
#5 龙虾 (Lobster) 龙虾 (Lobster) +16.03%
#6 Collect on Fanable Collect on Fanable +14.73%
#7 Cysic Cysic +13.73%
#8 Ontology Gas Ontology Gas +13.53%
#9 o1.exchange o1.exchange +13.31%
#10 OpenGradient OpenGradient +11.75%
Coin of the day
GEKKO GEKKO
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Pozycja w akcjach #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Cena akcji
$4.74
Ostatnia synchronizacja: 2026-08-28
Kapitalizacja rynkowa
$1.12B
Zmiana (1 dzień)
-5.77%
Zmiana (1 rok)
-16.96%
Kraj
FR
Handel Inventiva S.A. (IVA)

Kategoria

Healthcare
Zyski dla Inventiva S.A. (IVA)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Inventiva S.A., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Inventiva S.A. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH